Details for Patent: 8,602,215

Which drugs does patent 8,602,215 protect, and when does it expire?

Patent 8,602,215 protects MULTAQ and is included in one NDA.

Summary for Patent: 8,602,215

Title:	Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Abstract:	The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps: a--initiate beta-blockers treatment at a low dose; b--performing a electrocardiogram (ECG) verification of good tolerability; c--increase of beta-blockers dose only if results in step b) are satisfying.
Inventor(s):	Radzik; Davide (Paris, FR)
Assignee:	Sanofi (Paris, FR)
Application Number:	13/172,984
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,602,215
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,602,215

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009	AB	RX	Yes	Yes						MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RHYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF